KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Net Income towards Common Stockholders: 2015-2025

Historic Net Income towards Common Stockholders for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $124.8 million.

  • BeOne Medicines' Net Income towards Common Stockholders rose 202.88% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year increase of 107.97%. This contributed to the annual value of -$644.8 million for FY2024, which is 26.87% up from last year.
  • As of Q3 2025, BeOne Medicines' Net Income towards Common Stockholders stood at $124.8 million, which was up 32.36% from $94.3 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Net Income towards Common Stockholders registered a high of $215.4 million during Q3 2023, and its lowest value of -$590.7 million during Q4 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$121.3 million (2024), whereas its average is -$118.7 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 754.48% in 2022, then surged by 202.88% in 2025.
  • BeOne Medicines' Net Income towards Common Stockholders (Quarterly) stood at -$590.7 million in 2021, then climbed by 24.61% to -$445.3 million in 2022, then climbed by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then spiked by 202.88% to $124.8 million in 2025.
  • Its Net Income towards Common Stockholders stands at $124.8 million for Q3 2025, versus $94.3 million for Q2 2025 and $1.3 million for Q1 2025.